Valuation: Processa Pharmaceuticals, Inc.

Market Cap 4.52M 4.04M 3.76M 3.42M 6.46M 438M 6.48M 45.25M 17.73M 223M 16.99M 16.62M 716M P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value -1.01M -904K -841K -765K -1.44M -97.95M -1.45M -10.12M -3.97M -49.94M -3.8M -3.72M -160M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.18%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Processa Pharmaceuticals, Inc.

1 day+12.59%
1 week-6.17%
Current month-7.32%
1 month-29.63%
3 months-19.58%
6 months-49.67%
Current year-47.22%
1 week 1.04
Extreme 1.041
1.87
1 month 1.04
Extreme 1.041
2.12
Current year 1.04
Extreme 1.041
3.8
1 year 1.04
Extreme 1.041
11.08
3 years 1.04
Extreme 1.041
450
5 years 1.04
Extreme 1.041
4,125
10 years 1.04
Extreme 1.041
125,195.11
Manager TitleAgeSince
Chief Executive Officer 52 08/08/2023
Investor Relations Contact 60 29/03/2011
Chief Administrative Officer 61 04/10/2017
Director TitleAgeSince
Chairman 73 29/03/2011
Chairman 60 16/08/2022
Director/Board Member 56 13/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
8/8/26 A Exercice

Chief Executive Officer

3,200 0.1156%
7/26/26 A Other

Chief Financial Officer

11,883 0.4293%
7/26/26 A Other

Chief Executive Officer

9,384 0.3390%
Change 5-day change 1-year change 3-year change Capi.($)
+12.59%-6.17%-87.30%-98.33% 4.52M
-2.59%-5.70%+40.86%+83.11% 72.13B
+3.23%-13.45%+6.00%+55.77% 49.41B
+1.56%+2.07%+5.03%+33.38% 47.24B
+0.87%-7.83%+296.82%+657.83% 40.32B
+0.39%-0.32%+29.55%+30.83% 42.61B
+1.24%-1.20%+0.96%+103.86% 39.81B
-2.13%-2.18%+7.51%+50.31% 30.52B
+5.32%+0.11%-8.77%-12.81% 23.13B
+3.78%+5.71%+16.43%-1.77% 21.09B
Average +2.40%-5.18%+30.71%+90.22% 36.63B
Weighted average by Cap. +0.74%-4.28%+46.74%+118.77%

Financials

2024 2025
Net sales - -
Net income -11.85M -10.58M -9.85M -8.96M -16.91M -1.15B -16.98M -118M -46.43M -585M -44.5M -43.53M -1.88B -13.56M -12.11M -11.27M -10.25M -19.35M -1.31B -19.44M -136M -53.14M -669M -50.93M -49.82M -2.15B
Net Debt -1.12M -998K -929K -845K -1.59M -108M -1.6M -11.18M -4.38M -55.16M -4.2M -4.11M -177M -5.54M -4.95M -4.6M -4.18M -7.9M -536M -7.93M -55.37M -21.69M -273M -20.79M -20.34M -877M
Projected Income Statement - Annual - Processa Pharmaceuticals, Inc.
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Employees
12
Date Price Change Volume
09/10/26 $1.520 +12.59% 2,947,199
08/10/26 $1.350 -4.93% 12,803
07/10/26 $1.420 -6.58% 12,904
06/10/26 $1.520 +2.01% 18,585
05/10/26 $1.490 -7.45% 25,737

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Processa Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. PCSA Stock